104632-27-1

Basic information

• Product Name: PRAMIPEXOLE HYDROCHLORIDE
• Synonyms: 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, (R)-;Kns 760704;Snd 919cl2x;DexpraMipexole (dihydrochloride);PraMipexole IMpurity D;(R)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride // (R)-Pramipexole dihydrochloride;(R)-4,5,6,7-Tetrahydro-6-(propylamino)-benzothiazole-2-amine dihydrochloride;RPPX
• CAS NO: 104632-27-1
• Molecular Formula: C10H19Cl2N3S
• Molecular Weight: 284.24896
• Mol File: 104632-27-1.mol

Chemical Properties

• Appearance: white to beige/
• Storage Temp.: ?20°C
• Solubility: H2O: >15mg/mL
• CAS DataBase Reference: PRAMIPEXOLE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PRAMIPEXOLE HYDROCHLORIDE(104632-27-1)
• EPA Substance Registry System: PRAMIPEXOLE HYDROCHLORIDE(104632-27-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 104632-27-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PRAMIPEXOLE HYDROCHLORIDE is used as a secondary standard for quality control in pharmaceutical formulations. It serves as a certified reference material for various analytical applications, including pharmaceutical release testing, method development for qualitative and quantitative analyses, and calibration requirements.
PRAMIPEXOLE HYDROCHLORIDE is used as an analytical tool for the determination of the analyte in pharmaceutical formulations using reversed-phase high-performance liquid chromatography and ultraviolet spectrophotometry techniques.
Used in Quality Control:
PRAMIPEXOLE HYDROCHLORIDE is used as a pharmaceutical secondary standard, providing a convenient and cost-effective alternative to the preparation of in-house working standards for pharmaceutical laboratories and manufacturers.
Used in Parkinson's Disease Treatment:
PRAMIPEXOLE HYDROCHLORIDE is used as a dopamine receptor agonist for the treatment of Parkinson's disease, helping to manage the symptoms and improve the quality of life for patients.
Used in Research:
(R)-PRAMIPEXOLE HYDROCHLORIDE is used as a negative control for the (S) form in the study of dopamine receptors, providing valuable insights into the receptor's activity and potential therapeutic applications.
Used in Amyotrophic Lateral Sclerosis (ALS) Research:
The cytoprotective effect of (R)-PRAMIPEXOLE HYDROCHLORIDE, without dopaminergic side effects, suggests its potential utility in the study and treatment of amyotrophic lateral sclerosis.

Biochem/physiol Actions

R-(+)-Pramipexole is a neuroprotective agent; weak non-ergoline dopamine agonist. R-(+)-Pramipexole has been found to have neuroprotective effects and is being investigated for treatment of ALS. It reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, R-(+)-Pramipexole has much lower dopamine agonist activity.

Upstream product

• 104632-28-2 (R)-(+)-pramipexole 
• 106092-11-9 (R)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-diamine 
• 106006-85-3 (+)-2-amino-6-propionamidotetrahydrobenzothiazole 
• 599-91-7 propyl tosylate 

Relevant articles and documents

Amide activation by TMSCl: Reduction of amides to amines by LiAlH 4 under mild conditions

An expeditious and practical method for the reduction of amides to amines is reported. The method consists of activation of amides with TMSCl followed by reduction with LiAlH4. Various amides/lactams including hindered amides and secondary amides gave the corresponding amines in good to excellent yields. This novel protocol has a wide substrate scope and shows good functional group tolerance with high stereoretention.

IMPROVED SYNTHESIS OF AMINE SUBSTITUTED 4,5,6,7-TETRAHYDROBENZOTHIAZOLE COMPOUNDS

The present invention is related to an improved process for the preparation of amino- substituted 4,5,6,7-tetrahydrobenzothiazole compounds of formula I, such as the compound 2- amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole. The invention furthe

FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE

The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.

COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE

Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/ protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.

PROCESS FOR THE PREPARATION OF PRAMIPEXOLE AND NEW ANHYDROUS FORMS OF ITS DIHYDROCHLORIDE

The present invention provides processes for the preparation of (-) pramipexole or an acid addition salt thereof of Formula I. The present invention further provides for the novel polymorphic Forms A and B of anhydrous pramipexole dihydrochloride.